The trial will enrol nearly 280 adult subjects with obesity. Credit: Hunterframe / Shutterstock. Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet ...

According to the advisory, alcohol is the “third leading preventable cause” of cancer in the US, following tobacco use and obesity. It underscored that alcohol consumption contributed to cancers of ...

Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...

said that alcohol was the third most common preventable cause of cancer after tobacco and obesity. "The direct link between alcohol consumption and cancer risk is well-established for at least ...

A huge fire that erupted at a clothing market in Ghana’s capital Accra has destroyed hundreds of livelihoods and businesses. The fire at Kantamanto Market – one of the world’s largest ...

“He joined the ancestors when I was 10 years old. I was supposed to come to Ghana with him,” she said. Bowers and her husband, Damon Smith, are among the 524 diaspora members, mostly Black ...

Beginning in early 2025, Ghana is allowing visa free entry to citizens of all countries in Africa, after president Nana Akufo-Addo gave the move the green light in December. It comes after a ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Wia dis foto come from, Ghana National Fire Service/Facebook Fire outbreak happun for Kantamanto market for Accra, Ghana, for di early hours of Thursday, and destroy ova 100 shops. Di fire wey ...

Credit: Andrey_Popov via Shutterstock. Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most ...

Credit: Ciara Kimsey / Shutterstock. Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.